150 related articles for article (PubMed ID: 33533245)
1. Inhibition of Tumor-Host Cell Interactions Using Synthetic Heparin Mimetics.
Gockel LM; Heyes M; Li H; Al Nahain A; Gorzelanny C; Schlesinger M; Holdenrieder S; Li JP; Ferro V; Bendas G
ACS Appl Mater Interfaces; 2021 Feb; 13(6):7080-7093. PubMed ID: 33533245
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Schlesinger M; Schmitz P; Zeisig R; Naggi A; Torri G; Casu B; Bendas G
Thromb Res; 2012 May; 129(5):603-10. PubMed ID: 22099706
[TBL] [Abstract][Full Text] [Related]
3. Binding between heparin and the integrin VLA-4.
Schlesinger M; Simonis D; Schmitz P; Fritzsche J; Bendas G
Thromb Haemost; 2009 Nov; 102(5):816-22. PubMed ID: 19888514
[TBL] [Abstract][Full Text] [Related]
4. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
Schlesinger M; Roblek M; Ortmann K; Naggi A; Torri G; Borsig L; Bendas G
Thromb Res; 2014 May; 133(5):855-62. PubMed ID: 24636486
[TBL] [Abstract][Full Text] [Related]
5. Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches.
Fritzsche J; Simonis D; Bendas G
Thromb Haemost; 2008 Dec; 100(6):1166-75. PubMed ID: 19132244
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulant Heparin Mimetics via RAFT Polymerization.
Nahain AA; Ignjatovic V; Monagle P; Tsanaktsidis J; Vamvounis G; Ferro V
Biomacromolecules; 2020 Feb; 21(2):1009-1021. PubMed ID: 31841320
[TBL] [Abstract][Full Text] [Related]
7. Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
Gerber U; Hoß SG; Shteingauz A; Jüngel E; Jakubzig B; Ilan N; Blaheta R; Schlesinger M; Vlodavsky I; Bendas G
Semin Thromb Hemost; 2015 Mar; 41(2):244-54. PubMed ID: 25682080
[TBL] [Abstract][Full Text] [Related]
8. Sulfonated RAFT Copolymers as Heparin Mimetics: Synthesis, Reactivity Ratios, and Anticoagulant Activity.
Nahain AA; Ignjatovic V; Monagle P; Tsanaktsidis J; Vamvounis G; Ferro V
Macromol Biosci; 2020 Sep; 20(9):e2000110. PubMed ID: 32627962
[TBL] [Abstract][Full Text] [Related]
9. Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4.
Schmitz P; Gerber U; Schütze N; Jüngel E; Blaheta R; Naggi A; Torri G; Bendas G
Thromb Haemost; 2013 Nov; 110(5):1046-54. PubMed ID: 24009013
[TBL] [Abstract][Full Text] [Related]
10. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
11. A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis.
Chen Y; Peng J; Han M; Omar M; Hu D; Ke X; Lu N
J Drug Target; 2015 May; 23(4):335-46. PubMed ID: 25541466
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model.
Sudha T; Phillips P; Kanaan C; Linhardt RJ; Borsig L; Mousa SA
Clin Exp Metastasis; 2012 Jun; 29(5):431-9. PubMed ID: 22415710
[TBL] [Abstract][Full Text] [Related]
13. Stepwise inhibition of T cell recruitment at post-capillary venules by orally active desulfated heparins in inflammatory arthritis.
Al Faruque H; Kang JH; Hwang SR; Sung S; Alam MM; Sa KH; Nam EJ; Byun YR; Kang YM
PLoS One; 2017; 12(4):e0176110. PubMed ID: 28419144
[TBL] [Abstract][Full Text] [Related]
14. Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo.
Zhang C; Liu Y; Gao Y; Shen J; Zheng S; Wei M; Zeng X
Int J Cancer; 2009 Nov; 125(9):2058-65. PubMed ID: 19598263
[TBL] [Abstract][Full Text] [Related]
15. Effects of bemiparin, dalteparin, and unfractionated heparin on platelet interaction with human subendothelium under flow conditions.
González-Correa JA; Arrebola MM; Mérida F; Navas MD; López-Villodres JA; Samanes F; Cruz JP
J Pharmacol Sci; 2008 May; 107(1):103-6. PubMed ID: 18490857
[TBL] [Abstract][Full Text] [Related]
16. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins.
Hostettler N; Naggi A; Torri G; Ishai-Michaeli R; Casu B; Vlodavsky I; Borsig L
FASEB J; 2007 Nov; 21(13):3562-72. PubMed ID: 17557930
[TBL] [Abstract][Full Text] [Related]
17. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
18. Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest.
Bereczky B; Gilly R; Rásó E; Vágó A; Tímár J; Tóvári J
Clin Exp Metastasis; 2005; 22(1):69-76. PubMed ID: 16132580
[TBL] [Abstract][Full Text] [Related]
19. [Chemical modification endows heparin with low anticoagulant and high antineoplastic activities].
Liang Y; Li LB; Zhang P; Wu CZ; Zhao SR; Zhang QW; Liu H; Jiang ZW
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jan; 35(1):40-6. PubMed ID: 25613607
[TBL] [Abstract][Full Text] [Related]
20. The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.
Gockel LM; Ponert JM; Schwarz S; Schlesinger M; Bendas G
Molecules; 2018 Oct; 23(11):. PubMed ID: 30356007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
